



16 September 2025

Director Loans



Key Highlights

-  Managing Director, Dr Oludare Odumosu and Non-Executive Director and Dr Donna Gentile O'Donnell will collectively provide a total of USD\$150,000 unsecured loan notes to the Company on attractive terms.
-  Funds received will be used for general working capital purposes.
-  Subject to shareholder approval, the loan note will become convertible into shares at the higher of USD\$0.2585 and the 15-day VWAP prior Zelira electing to convert.

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, advises that Dr Oludare Odumosu and Dr Donna Gentile O'Donnell have executed working capital loan notes ("Loan Notes"), of USD\$100,000 and USD\$50,000 respectively, on attractive terms. The Loan Notes are considered by the Board (excluding Dr Odumosu and Dr O'Donnell) to be on terms favourable to the Company particularly considering current market and economic conditions. Funds received will be used for general working capital purposes.

Subject to shareholder approval to be sought at the upcoming 2025 Annual General Meeting, the Loan Note will become a Convertible Loan Note with a conversion price being the higher of USD \$0.2585 per share (being the 15-day VWAP of AUD\$0.388 converted into USD) and the 15-day VWAP prior Zelira electing to convert the Loan Note converted into USD. This represents an over 2.1% premium to the closing price on 15 September 2025. In the event that the Shareholders do not approve the conversion, Zelira shall pay a loan termination fee of 10%, at the same time that the Loan Notes are repaid.

Further terms of the Loan Note are annexed to this Announcement.

**For further information
please contact**

Company

Dr Oludare Odumosu
Managing Director & CEO
☎ +1 909 855 0675
✉ oodumosu@zeliratx.com

Australia

Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
☎ +61 8 6558 0886
Fax: +61 8 6316 3337
✉ enquiries@zeliratx.com

www.zeliratx.com

ACN 103 782 378

Investors

Rebecca Culbertson
Executive Director, Automic Group
☎ +61 400 955 295
✉ rebecca.culbertson@automicgroup.com.au

USA

5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
☎ +1 484 630 0650



Loan Note Terms

Lenders	1) Dr Oludare Odumosu 2) Dr Donna Gentile O'Donnell
Borrower	Zelira Therapeutics Limited
Loan Amount	1) USD\$100,000 in a single advance 2) USD\$50,000 in a single advance
Interest payments	20% per annum paid monthly in cash
Commencement Date	16 September 2025
Maturity	16 September 2026
Repayment	Repaid in cash at maturity
Security	The Loan Note will be unsecured
Arm's Length Terms	The Directors (other than Dr Oludare Odumosu and Dr Donna Gentile O'Donnell) confirm that in their opinion, the terms of the Loan Note are as favourable to the Company, if not more favourable than would be reasonable in the circumstances if the Company and Dr Oludare and Dr Donna Gentile O'Donnell were dealing at arm's length.
Shareholder approval	The Company does not consider shareholder approval to be required under the Loan Note, however subject to shareholder approval to be sought at the 2025 AGM (and on terms to be finalised between the Company and the Lenders), the Company will seek shareholder approval under ASX Listing Rule 10.11 and for all other purposes for the Loan Note, in full or in part, become a Convertible Loan Note which will include the capability for the Lender to elect that Loan Note to be repaid by issue of fully paid ordinary shares in the Company at a conversion price being the higher of USD\$0.2585 per share (being the 15-day VWAP of AUD\$0.388 converted into USD) and the 15-day VWAP prior Zelira electing to convert the Loan Note converted into USD
Use of Funds	Funds received will be used for general working capital purposes.

Zelira Therapeutics Ltd (ASX:ZLD,

OTCQB:ZLDAF) Zelira is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic noncancer pain as well as offering over the counter [OTC] products.

Zelira has established a special purpose vehicle (SPV) to conduct FDA Phase 1, Phase 2 and Phase 3 clinical trials for Zelira's proprietary and patent protected HOPE® 1. Zelira has contributed to the SPV its HOPE® 1 product, IP and real-world data for 55% equity ownership of the SPV. Cash investors will contribute a total of circa US\$35 million to fund the SPV and US FDA trials for HOPE® 1 in exchange for a cumulative equity interest of 45% of the SPV. Zelira will manage the SPV as part of its business platform. The SPV has appointed iNGENū CRO Pty Ltd (iNGENū) as its Contract Research Organisation (CRO) to lead the clinical validation and regulatory registration of the study product with the US FDA through the submission of an Investigative New Drug (IND) application.

In May 2023, Zelira completed an IRB approved strategically designed multi-arm, head-to-head study targeting diabetic nerve pain. The clinical trial included a comprehensive comparison against the widely recognised and highly successful

multi-billion dollar revenue generating drug Lyrica® (Pregabalin). With the findings underscoring the exceptional efficacy of our treatments in managing pain, with ZLT-L-007 demonstrating the most substantial reduction in pain severity, particularly at the 60-day and 90-day follow-up periods. Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi™, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.

Zelira's Rx business generates revenue from its proprietary medication, HOPE. The Company has two proprietary formulations under the HOPE® brand that are generating revenue in Australia, Washington, D.C., Pennsylvania and Louisiana. Zelira will also be expanding commercialisation of ZENIVOL® – the world's first clinically validated cannabinoid drug for treatment of chronic insomnia into Germany via its German commercialisation partner Adjupharm GmbH following recent approval from German regulatory authority BfArM. Zelira's OTC products in the oral and dermatology health care sectors are also generating revenue. Zelira, in partnership with SprinJeneCBD, launched a full line of oral care products, currently generating revenue in the US. Zelira also launched in 2021 the RAF FIVE™ brand, which consists of five OTC acne treatment products using a proprietary formulation incorporating cannabidiol (CBD).

For further information, please visit: zeliratx.com

